Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of Ingmar Bruns, M.D., Ph.D. as Chief Medical Officer, effective immediately.
November 2, 2020
· 4 min read